drugset / Trial / NCT01722318

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

NCT01722318

Phase 2 Completed 428 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C.

Timeline

Start
2012-11
Primary completion
2014-04
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Plecanatide Peptide 0.3 mg Oral
Comparator Plecanatide Peptide 1 mg Oral
Comparator Plecanatide Peptide 3 mg Oral
Comparator Plecanatide Peptide 9 mg Oral